868066-91-5

Basic information

• Product Name: 5-bromo-2-methylisoindolin-1-one
• Synonyms: 5-bromo-2-methylisoindolin-1-one;5-broMo-2-Methyl-2,3-dihydro-1H-isoindol-1-one;5-Bromo-2-methyl-2,3-dihydroisoindol-1-one
• CAS NO: 868066-91-5
• Molecular Formula: C₉H₈BrNO
• Molecular Weight: 226.072
• Mol File: 868066-91-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 356.2 °C at 760 mmHg
• Flash Point: 169.2 °C
• Appearance: /
• Density: 1.589
• Vapor Pressure: 2.98E-05mmHg at 25°C
• Refractive Index: 1.619
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.60±0.20(Predicted)
• CAS DataBase Reference: 5-bromo-2-methylisoindolin-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-methylisoindolin-1-one(868066-91-5)
• EPA Substance Registry System: 5-bromo-2-methylisoindolin-1-one(868066-91-5)

Safety Data

• Hazardous Substances Data: 868066-91-5(Hazardous Substances Data)

Usage

General Description

5-bromo-2-methylisoindolin-1-one is a chemical compound with the molecular formula C9H8BrNO. It is a benzene derivative and belongs to the class of organic compounds known as isoindolin-1-ones. 5-bromo-2-methylisoindolin-1-one is a white to light brown crystalline solid that is used as a building block in organic synthesis and pharmaceutical research. It has been studied for its potential applications in the development of new drugs, particularly in the field of neuroscience. The compound is known for its ability to interact with biological systems, making it a valuable tool for medicinal chemistry and drug discovery research. Its unique structure and properties make it an important molecule for the development of new therapeutic agents and potential pharmaceuticals.

InChI:InChI=1/C9H8BrNO/c1-11-5-6-4-7(10)2-3-8(6)9(11)12/h2-4H,5H2,1H3

Upstream product

• 74-89-5 methylamine 
• 78471-43-9 methyl 4-bromo-2-(bromomethyl)benzoate 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 552330-86-6 5-bromoisoindolin-1-one 
• 74-88-4 methyl iodide 
• 124-40-3 dimethyl amine 
• 64169-34-2 5-bromophthalide 
• 888030-82-8 (5-bromo-3H-isobenzofuran-1-ylidene)-isopropyl-amine 
• 888030-79-3 4-bromo-2-(hydroxymethyl)-N-methylbenzamide 

Downstream Products

• 1567836-38-7 2,4-difluoro-N-(5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)benzenesulfonamide 
• 1567837-79-9 4-fluoro-N-((5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)carbamothioyl)benzamide 
• 1567836-94-5 5-(5-(3-aminophenyl)thiophen-2-yl)-2-methylisoindolin-1-one 
• 1567837-01-7 2,4-difluoro-N-(5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)benzamide 
• 1254319-52-2 (S)-tert-butyl-4-(1-amino-3-(4-(2-methyl-3-oxoisoindolin-5-yl)phenyl)-1-oxopropan-2-yl carbamoyl)tetrahydro-2H-pyran-4-yl carbamate 
• 1579996-77-2 (S)-tert-butyl-2-((S)-1-amino-3-(4-(2-methyl-1-oxoisoindolin-5-yl)phenyl)-1-oxopropan-2-yl carbamoyl)piperidine-1-carboxylate 
• 1002309-19-4 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-isoindolin-1-one 

Relevant articles and documents

Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT

Herein, we report two promising compounds 30 and 36 possessing nanomolar FLT3 inhibitory activities (IC50 = 1.5-7.2 nM), high selectivity over c-KIT (>1000-fold), and excellent anti-AML activity (MV4-11 IC50 = 0.8-3.2 nM). Furthermore, these two compounds efficiently inhibited the growth of multiple mutant BaF3 cells expressing FLT3-ITD, FLT3-D835V/F, FLT3-F691L, FLT3-ITD-F691L, and FLT3-ITD-D835Y. Oral administration of 30 and 36 at 6 mg/kg/d could significantly suppress tumor growth in the MV4-11 cell-inoculated xenograft model, exhibiting tumor growth inhibitory rates of 83.5% and 95.1%, respectively. Importantly, 36 could prolong the mouse survival time in the FLT3-ITD-TKD dual mutation syngeneic mouse model (BaF3-FLT3-ITD-D835Y) at a dose of 6 mg/kg p.o. bid/4W. No clear myelosuppression was observed in the treated group of 36 in the MPO strain of zebrafish, even at 10 μM. In summary, our data demonstrated that 36 may represent a promising candidate for the treatment of FLT3 mutant AML.

Method of preparing Quinoline-5,8-dione derivatives for TGase 2 inhibitor

I Is -5,8- of the quinoline, dione derivative compound. of Formula I, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the compound of Formula, TGase 2 has, inhibitory effects TGase 2, and thus the pharmaceutical composition may be useful for preventing or treating disorders or diseases mediated by TGase 2 or inhibiting. (by machine translation)

Quinoline-5,8-dione derivatives for TGase 2 inhibitor, and the pharmaceutical composition comprising the same

The present invention relates to a quinolin-5,8-dione derivative compound represented by chemical formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The compound represented by chemical formula I of the present invention has a TGase 2 inhibitory effect, and the pharmaceutical composition comprising the same can be usefully used for preventing or treating disorders or diseases mediated by TGase 2 or response to TGase 2 inhibition.COPYRIGHT KIPO 2020